# Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Source: https://onco.cc/trials/nct01174121/  
OnCo record `nct01174121` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, fludarabine, cyclophosphamide and aldesleukin (high-dose IL-2) in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer is a phase 2, interventional study registered as NCT01174121 by National Cancer Institute (NCI), with a registry enrolment figure of 332 participants, started 2010-08-26 and due to reach its primary completion in 2028-12-27. Interventions recorded: Pembrolizumab (Keytruda); Fludarabine; Cyclophosphamide; Aldesleukin; Young TIL. Conditions listed: Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors. Primary outcome: Response rate. Colorectal eligibility wording from the registry: "* Patients with metastatic colorectal cancer must have received oxaliplatin or irinotecan". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT01174121
- Phase: 2
- Setting: A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 332

## Sources

- ClinicalTrials.gov NCT01174121: https://clinicaltrials.gov/study/NCT01174121

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct01174121.json